Outcome measures at three months were
very favorable to tinzaparin. The difference in major bleeding favored
Tinzaparin over UH during acute treatment. Bleeding rates during the
entire duration of the trial (including oral anticoagulation) were the
same. The differences in death and recurrent VTE approached statistical
significance, again in favor of tinzaparin. A subset of these patients
also had pulmonary embolism. Analysis of outcome data in PE patients
has recently been published. (Hull, et al. Arch Intern Med 2000; 160:
229-36)
